Control-IQ+ represents the next generation of the company’s advanced hybrid closed-loop insulin delivery algorithm. It has compatibility with both the company’s pump offerings, the t:slim X2 and Mobi pumps. The company said the algorithm is now available for people with type 1 diabetes aged two years and older, as well as in adults with type 2 diabetes.

San Diego-based Tandem won FDA clearance for the next-generation algorithm at the end of last month. It joined Insulet in offering AID technology for the type 2 population. Medtronic plans to file with the FDA to expand its AID technology to type 2 later this year as well.